As of the latest available data for Q3'25, Eli Lilly (LLY) reported an ROE of 23.46%, an ROA of 4.86%, and an ROIC of 7.81%. These figures reflect a strong rebound from the previous quarter, with all three profitability metrics showing notable improvement. From Q1'23 to Q3'25, the chart demonstrates a generally upward trend in ROE, ROA, and ROIC, despite some volatility, particularly in Q3'23 when all metrics briefly turned negative or declined sharply. After this dip, each metric recovered steadily, with significant peaks observed in Q4'24 and Q2'25. The overall trend suggests improving operational efficiency and profitability for LLY over the covered period, with the most recent quarters maintaining higher levels compared to early 2023.